Analysis of the relationship between the names and pharmacodynamics of pitobrutinib/pirtobrutinib and jepali

Pirtobrutinib/Pirtobrutinib (Pirtobrutinib) is a new generation of highly selective non-covalent BTK inhibitor, and its trade name is "Zepari" after it was officially launched in China. The two are actually different naming methods for the same drug: Pitobrutinib is its international generic name (INN), while "Jepali" is the brand name used by pharmaceutical companies in the Chinese market. Since Jepali is an original new drug, its research and development background, pharmacological mechanism and clinical data are completely consistent with Pitobrutinib, so patients do not need to worry about any changes in the efficacy of the drug after the name change.

In terms of its pharmacodynamic mechanism, the biggest feature of pitubrutinib (Zepali) is its non-covalent and reversible binding BTK, which is different from early covalent binding BTK inhibitors such as ibrutinib and acalabrutinib. Its advantage is that it can overcome the resistance problem caused by BTK C481 mutation, so it can still maintain high inhibitory activity for patients who have relapsed or become drug-resistant after multiple lines of treatment. This is one of the reasons why the drug is regarded as the "core drug of next-generation BTK targeted therapy", and these clinical advantages remain unchanged under the trade name "Jepali".

From the perspective of efficacy data, pitubrutinib has performed well in a number of international BRUIN studies, especially in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and various B Showing significant response rates in cellular malignancies. Its advantage is not only that it can cope with drug-resistant mutations, but also shows better safety: arrhythmia, bleeding, skin reactions and other adverse reactions that are common with traditional BTK inhibitors have a lower incidence rate. Therefore, when the drug enters the Chinese market under the trade name "Jepali", its efficacy logic and safety characteristics completely follow the original research system. The brand name is only used for marketing identification and does not change the pharmaceutical essence.

In general,"Pitubrutinib" represents the internationally accepted academic name, while "Jepari" represents the officially launched brand name for domestic patients. The two have the same intrinsic ingredients, the same efficacy, and the same indications. The difference in name will not affect efficacy, nor will it change clinical usage standards. When patients inquire about drug information or purchase, they only need to understand "Jepali is pitubrutinib" to avoid confusion between drug names and ensure smooth acceptance of standardized treatment.

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216059s002lbl.pdf